Anat Loewenstein, MD, MHA, is Professor and Director of the Division of Ophthalmology the Tel Aviv Medical Center, VP Ambulatory Services Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, Israel, and President of EURETINA. Her main field of interest is the investigation of drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of retinal disease.
She has been leading several cutting-edge technologies implemented in large scale clinical trials and in clinical setting: the home OCT, a first-of-a-kind artificial intelligence-enabled algorithm for monitoring retinal diseases, utilizing an OCT device in the patient’s own home, and the development of a technology implementing virtual reality in vitreoretinal surgery to replace the standard operating microscope. Professor Loewenstein was pivotal in the early development of the Port Delivery System, an innovative, FDA approved, intraocular drug delivery system. She serves on advisory boards of most large current pharmaceutical companies.
She published more than 500 papers in peer reviewed journals, and contributed multiple chapters to ophthalmology textbooks. She serves as the Editor-in-Chief of the Journal Case Reports in Ophthalmology, associate editor of Investigative Ophthalmology & Visual Science Journal, the European Journal of Ophthalmology, and Ophthalmologica.
Professor Loewenstin has many additional national and international roles as a leader in the field of retinal disease: is a member of the National Council of Surgery, a member of the Israeli Academy of Medicine, a member of the Academia Ophthalmological Internationalis, leads mentorship groups of ARVO, EURETINA, and programs sponsored by industry. She currently serves on the Board of NotalVision and Pulsenmore companies as well as on the board of ESASO (European school for advanced studies in ophthalmology) and previously was a board member at Given Imaging.